SCN4A Gene

SCN4A Gene

Overview

SCN4A Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SCN4A Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SCN4A</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Sodium Voltage-Gated Channel Alpha Subunit 4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q23.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6328</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000007314</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q9UQD0 (Nav1.4)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Voltage-gated sodium channel (Nav channel)</td>
</tr>
<tr>
<td class="label">Variant Type</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Missense</td>
<td>Gain-of-function</td>
</tr>
<tr>
<td class="label">Missense</td>
<td>Loss-of-function</td>
</tr>
<tr>
<td class="label">Missense</td>
<td>Mixed</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>SCN4A Channelopathy</td>
</tr>
<tr>
<td class="label">Onset</td>
<td>Childhood/adolescence</td>
</tr>
<tr>
<td class="label">Attack patterns</td>
<td>Episodic weakness</td>
</tr>
<tr>
<td class="label">CK levels</td>
<td>Normal to elevated</td>
</tr>
<tr>
<td class="label">EMG</td>
<td>Myotonic discharges</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">18 edges</a></td>
</tr>
</table>

SCN4A encodes Nav1.4, the principal voltage-gated sodium channel alpha subunit expressed predominantly in skeletal muscle. It is a canonical excitability gene with well-established disease associations in periodic paralysis and nondystrophic myotonia["@cannon2018"][@ptacek2000][@cannon2010]. While SCN4A is not classified as a primary neurodegenerative disease gene, its channel biology provides important insights into membrane excitability alterations observed in [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), [Parkinson's disease](/diseases/parkinsons-disease), and related neuromuscular complications of neurodegeneration["@waerman2020"][@finsterer2019].

Gene Information

Protein Structure and Function

Channel Architecture

Nav1.4 is a large transmembrane protein comprising four homologous domains (I-IV), each containing six transmembrane segments (S1-S6)[@cannon2018][@ptacek2000]. The S4 segments in each domain serve as voltage sensors, containing positively charged arginine and lysine residues that move outward upon depolarization to initiate channel activation[@ptacek2000][@cannon2010]. The pore-forming region is formed by the S5-S6 segments, which create the selective filter allowing sodium ions to pass through the membrane[@cannon2018][@ptacek2000].

Key structural features:

• Voltage-sensing domain (VSD): Four S4 segments that detect membrane depolarization
• Activation gate: Gate formed by S6 segments that opens upon depolarization
• Inactivation gate: Intracellular loop between domains III and IV that closes rapidly after activation
• Selective filter: P-loop region (SS1-SS2) that confers Na+ selectivity[@ptacek2000][@cannon2010]

Gating Mechanisms

The sodium current (INa) through Nav1.4 exhibits complex gating behavior essential for muscle excitability[@ptacek2000][@cannon2010]:

Mutations affecting these gating processes produce the channelopathies associated with SCN4A[@ptacek2000][@cannon2010][@finsterer2019].

Disease Associations

Periodic Paralysis

Hyperkalemic Periodic Paralysis (HyperKPP)

Gain-of-function mutations in SCN4A cause hyperkalemic periodic paralysis by producing persistent inward sodium current that depolarizes the muscle membrane, leading to weakness[@cannon2010][@finsterer2019]. The depolarization inactivates normal sodium channels, rendering muscle fibers inexcitable during attacks[@cannon2010].

Key features:

• Onset typically in childhood or adolescence
• Attacks triggered by rest after exercise, potassium-rich foods, or stress
• Serum potassium elevated during attacks
• Attack duration: minutes to hours[@finsterer2019]

Hypokalemic Periodic Paralysis (HypoKPP)

While primarily caused by CACNA1S mutations, certain SCN4A variants can produce HypoKPP phenotypes[@cannon2010][@finsterer2019]. These mutations stabilize the channel in a leaky state that is sensitive to membrane depolarization by hypokalemia[@cannon2010].

Nondystrophic Myotonias

Paramyotonia Congenita

Caused by mutations that impair channel inactivation, leading to myotonia (muscle stiffness) that paradoxically worsens with continued exercise (paradoxical myotonia)[@ptacek2000][@finsterer2019].

Sodium Channel Myotonia

Mutations causing gain-of-function without significant paralysis produce myotonia without periodic paralysis[@ptacek2000][@finsterer2019].

SCN4A in Neurodegenerative Context

While SCN4A is primarily expressed in skeletal muscle, research has revealed important connections to neurodegenerative diseases[@waerman2020][@finsterer2019][@van2010]:

Amyotrophic Lateral Sclerosis (ALS)

• Ion channel dysregulation: ALS motor [neurons](/entities/neurons) exhibit altered sodium channel expression and function[@waerman2020]
• Hyperexcitability: Early-stage ALS shows motor neuron hyperexcitability, potentially involving sodium channel modifications[@waerman2020]
• Differential diagnosis: SCN4A channelopathies can mimic ALS-like weakness, requiring genetic testing for distinction[@waerman2020][@finsterer2019]
• Therapeutic implications: Sodium channel blockers (e.g., mexiletine) are used in both SCN4A myotonia and ALS symptomatic management[@waerman2020][@van2010]

Parkinson's Disease (PD)

• Muscle involvement: PD patients may develop muscle weakness that can involve sodium channel dysfunction[@finsterer2019]
• Drug-induced channelopathy: Some PD medications can precipitate channelopathy-like symptoms[@finsterer2019]
• Differential diagnosis: Distinguishing PD-related weakness from primary channelopathies[@finsterer2019]

Charcot-Marie-Tooth Disease (CMT)

• Overlap syndromes: Some SCN4A mutations cause peripheral neuropathy phenotypes overlapping with CMT[@finsterer2019]
• Axonal excitability: Studies show sodium channel dysfunction in CMT type 1 and type 2[@finsterer2019]

Molecular Mechanisms in Neurodegeneration

Excitotoxicity Connection

Sodium channel dysfunction contributes to excitotoxicity through several mechanisms[@waerman2020][@van2010]:

Therapeutic Targeting

Sodium channels are therapeutic targets in neurodegeneration[@waerman2020][@van2010]:

• Mexiletine: FDA-approved for myotonia, used off-label in ALS for hyperexcitability
• Riluzole: Primary ALS therapy targets sodium channels to reduce glutamate release
• Lacosamide: Anti-seizure medication with sodium channel-modulating properties[@waerman2020][@van2010]

Genetics and Variants

Over 200 pathogenic variants in SCN4A have been described[@ptacek2000][@cannon2010][@finsterer2019]:

Genotype-Phenotype Correlations

Specific amino acid residues correlate with clinical phenotypes[@ptacek2000][@cannon2010]:

• Mutations in S4 segments - HyperKPP
• Mutations in inactivation gate - Paramyotonia
• Mutations in domain II - Mixed phenotypes[@ptacek2000][@finsterer2019]

Clinical Testing and Management

Diagnostic Approach

Management Strategies

• Acute attack management: Potassium administration (HyperKPP) or glucose/insulin (HypoKPP)
• Preventive therapy: Acetazolamide, dichlorphenamide
• Lifestyle modifications: Dietary potassium control, avoid triggers
• Symptomatic treatment: Mexiletine for myotonia[@ptacek2000][@finsterer2019]

Differential Diagnosis in Neurodegeneration

Distinguishing Channelopathies from Neurodegeneration

When evaluating patients with weakness in the context of suspected neurodegenerative disease, clinicians must consider SCN4A channelopathies as differential diagnoses[@waerman2020][@finsterer2019][@van2010]:

Key Distinctions

Comorbidities

• Some patients with ALS may carry SCN4A variants
• Pre-existing SCN4A channelopathy may modify ALS presentation
• Genetic testing helps clarify diagnosis[@waerman2020][@finsterer2019]

Pharmacogenomics

Drug Responses in SCN4A Variants

Different SCN4A mutations confer varying drug responses[@ptacek2000][@finsterer2019][@van2010]:

Mexiletine

• Highly effective for paramyotonia congenita
• Reduces myotonia in most SCN4A myotonias
• May worsen certain gain-of-function variants[@ptacek2000][@finsterer2019]

Riluzole

• Primary ALS therapy with sodium channel-blocking activity
• May provide benefit in ALS patients with hyperexcitability
• Does not affect SCN4A channelopathies[@waerman2020][@van2010]

Acetazolamide

• Effective preventive therapy for periodic paralysis
• Works through metabolic effects, not direct channel modulation
• Reduces attack frequency in HyperKPP[@finsterer2019]

Research Directions

Current research areas include[@ptacek2000][@cannon2010][@waerman2020][@van2010]:

• Precision medicine: Variant-specific therapies based on gating defects
• Gene therapy: Antisense oligonucleotides targeting mutant transcripts
• Channel modulators: Novel compounds with improved specificity
• Neurodegeneration links: Understanding SCN4A contributions to ALS and PD mechanisms

Emerging Therapies

Animal Models

Mouse models carrying SCN4A mutations recapitulate human channelopathy phenotypes[@cannon2010][@finsterer2019]:

• Transgenic mice: Express mutant Nav1.4, show paralysis episodes
• Knock-in models: Patient-specific mutations produce relevant phenotypes
• Phenotypic characterization: Supports drug testing for channelopathy treatments[@cannon2010]

Model Systems in Neurodegeneration

• Drosophila models: Potassium channel studies in fruit flies
• Zebrafish: Neuromuscular development and channel function
• Induced pluripotent stem cells: Patient-derived muscle cells[@cannon2010]

Cross-Linked Pathways

• [Voltage-gated sodium channels](/mechanisms/voltage-gated-sodium-channels)
• [Ion channelopathies](/mechanisms/ion-channelopathies)
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [Muscle ion channels](/mechanisms/muscle-ion-channels)
• [Periodic paralysis syndromes](/diseases/periodic-paralysis)

See Also

• [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [Voltage-gated sodium channels](/mechanisms/voltage-gated-sodium-channels)
• [Ion channelopathies](/mechanisms/ion-channelopathies)
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Muscle ion channels](/mechanisms/muscle-ion-channels)
• [Periodic paralysis syndromes](/diseases/periodic-paralysis)

External Links

• [Ensembl: ENSG00000007314](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000007314)

Brain Atlas Resources

• [Allen Human Brain Atlas*: [Gene expression search](https://human.brain-map.org/microarray/search/show?search_term=SCN4A)](/datasets/allen-human-brain-atlas)
• [Allen Mouse Brain Atlas*: [Gene search](https://mouse.brain-map.org/search/index.html?query=SCN4A)](/projects/brain-atlas)
• [Allen Cell Type Atlas*: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and](/cell-types/atlas)-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=SCN4A)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SCN4A Gene discovered through SciDEX knowledge graph analysis: